CA-AGENDIA,-INC.
18.11.2020 13:02:29 CET | Business Wire | Press release
Agendia, Inc ., a world leader in precision oncology for breast cancer, and Paige , a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005250/en/
“Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally,” said Mark Straley, Chief Executive Officer of Agendia. “Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today.”
The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.
“As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come.”
For more information, please visit Agendia.com and Paige.ai.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai , https://www.paigeplatform.com , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005250/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUR Appoints Dr. Daniel Klier as Chief Executive Officer24.2.2026 09:00:00 CET | Press release
Seasoned sustainability and climate finance leader to guide PUR’s next phase of growth PUR (the “Company”), a pioneer in Nature-based Solutions, today announced the appointment of Dr. Daniel Klier as Chief Executive Officer, subject to regulatory approval. Founded nearly two decades ago, PUR partners with farming communities globally to deliver agroforestry, reforestation, and landscape restoration projects. The Company generates verified carbon reductions and carbon credits that help corporates reduce supply chain emissions through high-integrity insetting and climate contributions within and beyond their own value chains, while improving soil health, water resources, and long-term farm productivity. PUR is a recognized leader in resilient coffee and cocoa value chains, reforestation, mangrove restoration, and ecosystem conservation, delivering measurable benefits for ecosystems, agriculture, and farming communities. Dr. Klier’s appointment marks the next phase of PUR’s development as
BearingPoint launches new services to help organizations gain full software transparency and meet EU Cyber Resilience Act requirements ahead of the 2027 deadline24.2.2026 09:00:00 CET | Press release
BearingPoint’s new SBOM Management and CRA Compliance Services strengthen software supply chain security. BearingPoint announces the launch of two new service offerings designed to address the growing complexity of software supply chains and the upcoming regulatory requirements under the EU Cyber Resilience Act (CRA): SBOM Management Services and CRA Compliance Services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224192962/en/ BearingPoint announces the launch of two new service offerings designed to address the growing complexity of software supply chains and the upcoming regulatory requirements under the EU Cyber Resilience Act (CRA): SBOM Management Services and CRA Compliance Services. Modern software products often contain thousands of components, many of which are open source or sourced from third-party suppliers. As supply chain attacks become more frequent and regulations tighten, organizations need complete v
Thredd Powers MuchBetter's Expansion into Israel, Supporting Global Growth Strategy24.2.2026 09:00:00 CET | Press release
Launch reflects accelerating international momentum across the UK, Canada and beyond Thredd, the AI-first issuer processing platform, today announced the expansion of their partnership with MuchBetter, the consumer wallet and prepaid card platform, supporting the company’s launch in Israel. This marks the latest milestone in MuchBetter’s international expansion, powered by Thredd, following the successful deployment of their programme in the UK and Canada. Through the partnership, Thredd is providing processing infrastructure for MuchBetter’s prepaid card and digital wallet programme, enabling consumers in Israel to securely load funds and make payments using physical and virtual cards, with additional form factors planned as the programme scales. “International expansion is a core part of MuchBetter’s growth strategy, and Thredd has been a critical partner in helping us move quickly and confidently into new markets,” said Israel Rosenthal, Founder and CEO of MuchBetter. “Launching in
Cambridge Drives a New Era of Digital Maturity for the Age of AI24.2.2026 08:10:00 CET | Press release
Updated Cambridge Primary and Lower Secondary Digital Literacy curricula provide future-facing framework for responsible AI and media literacyBold curriculum update empowers children to think critically, act responsibly and shape, not just consume, technology As digital literacy moves to the forefront of education reforms worldwide, the International Education group at Cambridge University Press & Assessment (Cambridge) today announces a major transformation of its Cambridge Primary and Lower Secondary Digital Literacy curricula, redefining what it means for young people to thrive in an AI-powered world. Designed for learners aged 5–14, the updated Cambridge Primary Digital Literacy and Lower Secondary Digital Literacy go beyond teaching children how to use technology. They foster digital maturity, equipping students with the judgement, critical thinking and confidence to decide why, when and how technology should be used. The refreshed curricula provide schools with a clear, future-fa
Cubans Protest EU Financing of Havana Regime Amid Rising Tensions24.2.2026 08:05:00 CET | Press release
Cubans from across the United States gathered today in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s complicity in financing Cuba’s communist state. Protesters held signs reading, “EU, don’t fund the dictatorship,” “Democracies should not fund dictatorships,” and “This march would get me killed in Cuba.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223106922/en/ Cubans from across the United States gathered yesterday in Washington, D.C., outside the Delegation of the European Union, to denounce the EU’s role in financing Cuba’s communist state. The demonstration featured leading Cuban opposition groups including the Assembly of the Cuban Resistance and Cuban Freedom March along with former Cuban political prisoners, Veterans of the Bay of Pigs, Florida State Senator Alexis Calatayud, Miss Universe Cuba 2025 Lina Luaces, and television personality Lili Estefan. Photo: Assembly of th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom